The primary objective of this study is to assess the ability of EpanovaTM Soft Gelatin
Capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (Crohn's Disease
Activity Index CDAI < 150) in CD patients in whom remission, stable for at least three months
and no longer than one year, has been induced by corticosteroids, azathioprine/6-MP,
methotrexate, 5-ASA or antibiotics.
Secondary objectives are to assess the:
efficacy of Epanova versus placebo by Crohn's Disease Activity Index (CDAI), Investigator and
Subject Global Ratings, employment status and use of CD related medical visits in subjects
with CD in remission
safety and tolerability of Epanova
ability of Epanova to maintain the quality of life of CD patients in remission